Vilazodone for the Treatment of Depression: An Update / 전남의대학술지
Chonnam Medical Journal
;
: 91-100, 2016.
Artigo
em Inglês
| WPRIM
| ID: wpr-94059
ABSTRACT
Vilazodone is a novel antidepressant having a selective serotonin (5-HT) reuptake inhibitor and 5-HT(1A) receptor partial agonist profile, so it has been regarded as a serotonin partial agonist-reuptake inhibitor (SPARI). We aimed to provide Vilazodone's clinical implications mainly by reviewing published clinical trials. Vilazodone has been speculated to have three potential benefits including faster onset of action, greater efficacy, and better tolerability owning to its SPARI properties. However, no studies conducted so far have directly proven the above speculations. Five initial phase II trials failed to distinguish vilazodone from placebo in the treatment of MDD, but 4 randomized clinical trials (RCT), 3 post-hoc or pooled analysis, 1 long-term open label study, and a meta-analysis showed vilazodone's superior efficacy over placebo. The studies also showed vilazodone is generally safe and tolerable. However, diarrhea, nausea, headache, dizziness, dry mouth, and insomnia warrant close attention in clinical practice because they have been constantly noted throughout the clinical studies. 2 RCTs recently documented the efficacy and safety of vilazodone in patients with generalized anxiety disorder, which could be a start of broadening vilazodone's usage or FDA approval in diverse anxiety disorders.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Transtornos de Ansiedade
/
Serotonina
/
Inibidores Seletivos de Recaptação de Serotonina
/
Receptor 5-HT1A de Serotonina
/
Depressão
/
Diarreia
/
Tontura
/
Cloridrato de Vilazodona
/
Cefaleia
/
Distúrbios do Início e da Manutenção do Sono
Tipo de estudo:
Ensaio Clínico Controlado
Limite:
Humanos
Idioma:
Inglês
Revista:
Chonnam Medical Journal
Ano de publicação:
2016
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS